Back to Search
Start Over
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
- Source :
-
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 18; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 18. - Publication Year :
- 2021
-
Abstract
- Coronavirus disease (COVID-19) is a contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, which depletes B lymphocyte cells and therefore disables the production of neutralizing antibodies. The combined use of external anti-viral agents like convalescent plasma, IVIG and Remdesivir successfully helped the patient's immune system to eradicate the virus without B-cell population recovery. In vitro studies showed that convalescent plasma is the main agent that helped in eradicating the virus.
- Subjects :
- Adenosine Monophosphate analogs & derivatives
Alanine analogs & derivatives
Animals
Antibodies, Neutralizing therapeutic use
Antiviral Agents therapeutic use
COVID-19 diagnostic imaging
Chlorocebus aethiops
Humans
Immunization, Passive
Immunocompromised Host
Rituximab therapeutic use
T-Lymphocytes immunology
Vero Cells
COVID-19 Serotherapy
Antibodies, Viral immunology
B-Lymphocytes immunology
COVID-19 immunology
COVID-19 therapy
SARS-CoV-2 immunology
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1422-0067
- Volume :
- 22
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- International journal of molecular sciences
- Publication Type :
- Report
- Accession number :
- 34445605
- Full Text :
- https://doi.org/10.3390/ijms22168902